<DOC>
	<DOCNO>NCT02675530</DOCNO>
	<brief_summary>This study investigate common feature electrophysiological measure schizophrenia effect NMDA antagonist ketamine healthy volunteer .</brief_summary>
	<brief_title>Parallel Effects Schizophrenia N-methyl-D-aspartate ( NMDA ) Antagonism</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Subjects Ketamine experiment ( Healthy control experiment ) : 1 . Male female 2 . 2145 year old 3 . Deemed healthy Structured Clinical Interview DSMNP ( SCIDNP ) collateral information . Subjects need provide name person , preferably family member , research team contact corroborate information . 1 . Lifetime diagnosis DSMIV substance dependence ( except caffeine nicotine ) . 2 . Substance abuse , per clinical judgment , past 1 year . 3 . Current past DSMIV AxisI diagnosis . 4 . A history significant medical/neurological disease cardiac , thyroid , renal , hepatic neurological . Unstable medical condition base EKG , vital sign , physical examination laboratory workup . 5 . A hearing deficit great 30 dB ear detect use WelchAllyn audioscope ( 500 , 1000 , 2000 4000 Hz threshold evaluate ) screening . 6 . Major current recent ( &lt; 6 week ) stressor . 7 . History counseling , except counsel life circumstance disorder ( e.g. , bereavement , divorce ) opinion investigator , clinically significant . 8 . Lifetime history treatment psychotropic medication &gt; 1 month duration suggestive psychiatric illness . 9 . Current past Axis I diagnosis schizophrenia bipolar disorder firstdegree relative . 10 . Any medication could interfere either safety study and/or outcome measure . 11 . Use illicit substance 4 week prior begin study participation . 12 . Any history indicate learn disability , mental retardation , attention deficit disorder . 13 . History head injury loss consciousness great fifteen minute . 14 . Any condition medication , opinion investigator would preclude participation study . 15 . NonEnglish speaking . 16 . Known sensitivity ketamine . Subjects Schizophrenia experiment : Inclusion Criteria control subject : 1 . Male female 2 . 2145 year old 3 . No past present Axis I diagnosis , determine SCIDNP Exclusion Criteria control subject : 1 . Lifetime diagnosis DSMIV substance dependence ( except caffeine nicotine ) . 2 . Substance abuse , per clinical judgment , past 1 year 3 . A history significant medical/neurological disease cardiac , thyroid , renal , hepatic neurological . 4 . A hearing deficit great 30dB ear detect use WelchAllyn audioscope ( 500 , 1000 , 2000 4000 Hz threshold evaluate ) screening . 5 . Axis I diagnosis schizophrenia bipolar disorder firstdegree relative . 6 . History head injury loss consciousness great fifteen minute 7 . Any condition medication , opinion investigator would preclude participation study . 8 . NonEnglish speaking . Inclusion Criteria patient : 1 . Male female 2 . 2145 year old 3 . Diagnosed DSMIV schizophrenia base SCIDIP interview patient . 4 . Stable dose antipsychotic medication least 2 week prior begin study participation . 5 . Score either 13 ( high functioning ) range 57 ( low functioning ) range Global Functioning Scale MSIF base screen interview . 1 . Lifetime diagnosis DSMIV substance dependence ( except caffeine nicotine ) . 2 . Substance abuse , per clinical judgment , past 1 year 3 . A history significant medical/neurological disease cardiac , thyroid , renal , hepatic neurological . 4 . A hearing deficit great 30dB ear detect use WelchAllyn audioscope ( 500 , 1000 , 2000 4000 Hz threshold evaluate ) screening . 5 . History head injury loss consciousness great fifteen minute . 6 . Any condition medication , opinion investigator would preclude participation study . 7 . NonEnglish speaking .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>NMDA</keyword>
	<keyword>glutamate</keyword>
	<keyword>schizophrenia</keyword>
</DOC>